Could a custom vaccine slow Alzheimer's? new trial begins

NCT ID NCT05834296

Ongoing Disease control Sponsor: Alzamend Neuro, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase trial tests a personalized vaccine (ALZN002) made from a patient's own immune cells, designed to train the body to attack amyloid plaques in the brain. Thirty people with mild-to-moderate Alzheimer's will receive either the vaccine or a placebo. The main goal is to check safety, but researchers will also look for signs of slowing cognitive decline.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: personalized dendritic cell vaccine (ALZN002) made from the patient's own immune cells
What this could lead to: If it works, this could slow or stop Alzheimer's progression by training the immune system to clear amyloid plaques from the brain.
What could go wrong: This is a very early, small trial (30 people) testing safety first. The vaccine may not work, could cause side effects, and even if successful, it would manage the disease, not cure it.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DISEASE

Contacts and locations

Locations

First Excellent Research Group

Doral, Florida, 33186, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.